Literature DB >> 21719245

Inhibition of cyclooxygenase-2 promotes the stimulatory action of adenosine A₃ receptor agonist on hematopoiesis in sublethally γ-irradiated mice.

Michal Hofer1, Milan Pospíšil, Ladislav Dušek, Zuzana Hoferová, Lenka Weiterová.   

Abstract

Mouse hematopoiesis, suppressed by a sublethal dose of ionizing radiation, was the target for combined therapy with a cyclooxygenase-2 (COX-2) inhibitor meloxicam and an adenosine A₃ receptor agonist IB-MECA. The drugs were administered in an early postirradiation treatment regimen: meloxicam was given in a single dose 1hour after irradiation, IB-MECA in two doses 24 and 48hours after irradiation. Treatment-induced changes in several compartments of hematopoietic progenitor and precursor cells of the bone marrow were evaluated on day 3 after irradiation. Values of hematopoietic progenitor cells for granulocytes/macrophages and erythrocytes (GM-CFC and BFU-E, respectively), as well as those of proliferative granulocytic cells were found to be significantly higher in the mice treated with the drug combination in comparison to irradiated controls and attained the highest increase factors of 1.6, 1.6, and 2.6, respectively. The study emphasizes the significance of the combined treatment of suppressed hematopoiesis with more agents. Mechanisms of the action of the individual compounds of the studied drug combination and of their joint operation are discussed.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21719245     DOI: 10.1016/j.biopha.2011.04.033

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Lack of adenosine A3 receptors causes defects in mouse peripheral blood parameters.

Authors:  Michal Hofer; Milan Pospíšil; Ladislav Dušek; Zuzana Hoferová; Denisa Komůrková
Journal:  Purinergic Signal       Date:  2014-04-25       Impact factor: 3.765

2.  Does the administration of meloxicam before head and neck radiotherapy reduce the risk of mandibular osteoradionecrosis? An animal model study.

Authors:  Mayra Cristina Yamasaki; Gina Delia Roque-Torres; Leonardo Vieira Peroni; Eduarda Helena Leandro Nascimento; Benjamin Salmon; Matheus Lima Oliveira; Deborah Queiroz Freitas; Lourenço Correr-Sobrinho
Journal:  Clin Oral Investig       Date:  2021-01-02       Impact factor: 3.573

3.  Agonist of the adenosine A3 receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of γ-irradiated mice.

Authors:  Michal Hofer; Milan Pospíšil; Ladislav Dušek; Zuzana Hoferová; Denisa Komůrková
Journal:  Radiat Environ Biophys       Date:  2013-11-22       Impact factor: 1.925

Review 4.  Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?

Authors:  Michal Hofer; Zuzana Hoferová; Martin Falk
Journal:  Int J Mol Sci       Date:  2017-06-28       Impact factor: 5.923

Review 5.  Combining Pharmacological Countermeasures to Attenuate the Acute Radiation Syndrome-A Concise Review.

Authors:  Michal Hofer; Zuzana Hoferová; Daniel Depeš; Martin Falk
Journal:  Molecules       Date:  2017-05-19       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.